J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
Covid vaccine developers face nervous wait
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.
Moderna’s Covid-19 vaccine looks golden in oldies
Moderna gets a boost from data in older subjects and a potential logistical advantage.
Does FDA’s plasma nod set a dangerous precedent?
The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
The next triggers in Covid-19 vaccine development
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
